
doi: 10.1189/jlb.68.3.338
pmid: 10985249
Abstract CD4+ T cells and tissue macrophages are well defined as the major targets for human immunodeficiency virus type 1 (HIV-1) infection and replication, and their infection accounts for many aspects of HIV-1 pathogenesis in vivo. HIV-1 genotype and phenotype in monocytes and their potential roles in pathogenicity in vivo remain unknown. Herein is an overview of our initial work on HIV-1 genotype in purified CD14+ monocytes isolated longitudinally during the course of infection starting from the time of infection. Our data provide evidence for HIV-1 evolution in monocytes and their role as a reservoir of HIV-1 in vivo. A better understanding of HIV-1 in monocytes may greatly help the development of new therapeutic strategies for HIV-1 infection.
CD4-Positive T-Lymphocytes, Genotype, Sequence Homology, Amino Acid, Molecular Sequence Data, Lipopolysaccharide Receptors, HIV Infections, HIV Envelope Protein gp120, Monocytes, HIV-1, Animals, Humans, Amino Acid Sequence
CD4-Positive T-Lymphocytes, Genotype, Sequence Homology, Amino Acid, Molecular Sequence Data, Lipopolysaccharide Receptors, HIV Infections, HIV Envelope Protein gp120, Monocytes, HIV-1, Animals, Humans, Amino Acid Sequence
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 21 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
